Perlegen Sciences

Perlegen Sciences
Mountain View, Calif.
Founded: 2001

Why It's Fierce: Perlegen Sciences was spun off from bioarray pioneer Affymetrix to help drug companies quickly identify promising drug targets from volumes of human genome data. The company is mapping 50 human genomes to identify unique genetic variations. Drug companies will use this information to create the first wave of genomics drugs. Pfizer, Eli Lilly, and Bristol-Myers Squibb signed long-term research deals with Perlegen in December, boosting the company's ambitious growth plan.

What to look for in 2003: Perlegen will sign additional partnerships this year, solidifying its leadership position in this emerging niche.

Perlegen Sciences

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.